Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
InDex Pharmaceuticals is developing cobitolimod for the treatment of moderate to severe ulcerative colitis
Capital Markets Day 2022
-
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2022
August 26, 2022 Regulatory
-
InDex Pharmaceuticals announces successful interactions with the PMDA for the clinical development of cobitolimod in Japan
August 16, 2022 Non Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q2 for January-June 2022 on August 26, 2022 at 08:00 a.m. CEST.
-
Presentation at Redeye investor AW in Gothenburg
-
Interim Report Q3 2022
-
Year-end Report 2022
Our phase III study CONCLUDE
Have a look at InDex’s corporate presentation
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
